Free Trial
→ Bill Gates’ is about to mint millionaires (again) with Stargate. (From Brownstone Research) (Ad)

Portage Biotech Q3 2023 Earnings Report

Portage Biotech logo
$4.57 -0.12 (-2.56%)
As of 02/21/2025 03:59 PM Eastern
Earnings History

Portage Biotech EPS Results

Actual EPS
-$5.80
Consensus EPS
-$5.40
Beat/Miss
Missed by -$0.40
One Year Ago EPS
N/A

Portage Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Portage Biotech Announcement Details

Quarter
Q3 2023
Date
11/29/2023
Time
Q2 2024 Earnings Release

Conference Call Resources

Powered by Quartr

Portage Biotech Earnings Headlines

Portage Biotech Inc.: Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
February 19 at 7:16 AM | finanznachrichten.de
Portage Biotech Granted Nasdaq Compliance Extension
February 12, 2025 | tipranks.com
Bill Gates’ is about to mint millionaires (again) with Stargate.
This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.
February 22, 2025 | Brownstone Research (Ad)
Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
February 12, 2025 | globenewswire.com
Portage Biotech Announces Completion of $2.15 Million Private Financing
January 30, 2025 | globenewswire.com
Portage announces relaunch of adenosine subsidiary as independently managed
January 7, 2025 | markets.businessinsider.com
See More Portage Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Portage Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Portage Biotech and other key companies, straight to your email.

About Portage Biotech

Portage Biotech (NASDAQ:PRTG), a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

View Portage Biotech Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles